2018
Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA)
Feinberg J, Elvin J, Bellone S, Santin A. Identification of ovarian cancer patients for immunotherapy by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Gynecologic Oncology 2018, 149: 36. DOI: 10.1016/j.ygyno.2018.04.081.Peer-Reviewed Original Research
2016
Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).
Santin A, Moore K, Gunderson C, Gowen K, Fabrizio D, Frampton G, Vergilio J, Suh J, Gay L, Ramkissoon S, Ali S, Miller V, Stephens P, Ross J, Sun J, Elvin J. Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). Journal Of Clinical Oncology 2016, 34: 5591-5591. DOI: 10.1200/jco.2016.34.15_suppl.5591.Peer-Reviewed Original Research